问题 › 我们不断打折才能赢得交易 › HealthTech与数字健康
常规折扣通常是证明问题和激励问题，几乎从来不是标价问题。 数字健康公司面临更难的结构性问题：结果风险签约速度快于公司验证自身能否承担的速度——12个月测量窗口对11个月销售周期。任何可信方案都必须同时纳入风险收入份额与参与率，而这两者通常分属不同系统，导致内部分析在此止步。
常规折扣通常是证明问题和激励问题，几乎从来不是标价问题。 数字健康公司面临更难的结构性问题：结果风险签约速度快于公司验证自身能否承担的速度——12个月测量窗口对11个月销售周期。任何可信方案都必须同时纳入风险收入份额与参与率，而这两者通常分属不同系统，导致内部分析在此止步。
当风险收入份额成为成交常规，合同份额实际锁定在折扣水平，任何更高锚点仅剩装饰作用。这会带来毛利之外的成本：它向支付方和提供者传递公司实际接受的归因结果价格，扭转预期需要很长时间。
驱动因素源于测量窗口。归因结果无法在11个月销售周期内展示，因为数据需要12个月，于是价格成为唯一可调变量。或者薪酬按成交logo和入组人数而非风险份额利润计算。或者每位代表都有PMPM让步审批权，因此被使用。
诊断在于数字模式。当更深风险份额或更低PMPM条款集中在特定季度或特定代表身上，而参与率相近时，原因在于激励和授权，而非结果经济学本身。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 风险份额或PMPM让步在季度末几周急剧上升
✓ 相同参与率和logo画像的交易中，不同代表同意的风险份额或PMPM条款差异很大
✓ 销售要求更大让步风险份额的权限，而非要求更多归因结果证明
通常会让情况更糟的做法。 将基础PMPM下调至匹配近期成交价位，这会重置锚点，并在随后两季度内产生同等让步。
It is for you if you run or finance a digital health company and discounts spike at period end. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 定价与收入优化, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
限制裁量权，按利润而非收入支付提成。打折是对收入指标配额加无限价格权限的理性反应。
不是——如果是有意用作交换条件，比如换取期限、量或参考案例。谈判结束时的本能反应，则是无谓让出毛利。
续约时提前通知并说明理由进行调整，接受部分流失。否则市场最终会发现永久的两套价格体系。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית